Oligonucleotides containing pyrazolo[3,4-D]pyrimidines for hybridization and mismatch discrimination

• US 6,127,121 A
• Filed: 04/03/1998
• Issued: 10/03/2000
• Est. Priority Date: 04/03/1998
• Status: Expired due to Term

• Current Assignee: ELITechGroup B.V. (ELITech Group SAS)
• Original Assignee: Epoch Pharmaceuticals, Inc.
• Inventors: Meyer, Rich B. Jr., Kutyavin, Igor V., Afonina, Irina A.
• Primary Examiner(s): Marschel, Ardin H.
• Application Number:
  US09/054,830
• Time in Patent Office: 914 Days
• Field of Search: 435/6, 435/91.2, 436/501, 536/22.1, 536/23.1, 536/24.1, 536/24.3-24.33, 935/77, 935/78
• US Class Current: 435/6.11
• CPC Class Codes: C12Q 1/6818 involving interaction of two or more labels, e.g. resonant energy transfer
• CPC Class Codes: C12Q 1/6827 for detection of mutation or polymorphism
• CPC Class Codes: C12Q 1/6832 Enhancement of hybridisation reaction
• CPC Class Codes: C12Q 2525/117 incorporating modified base
• CPC Class Codes: C12Q 2527/107 Temperature of melting, i.e. Tm

Abstract

Oligonucleotides in which one or more purine residues are substituted by pyrazolo[3,4-d]pyrimidines exhibit improved hybridization properties. Oligonucleotides containing pyrazolo[3,4-d]pyrimidine base analogues have higher melting temperatures than unsubstituted oligonucleotides of identical sequence. Thus, in assays involving hybridization of an oligonucleotide probe to a target polynucleotide sequence, higher signals are obtained. In addition, mismatch discrimination is enhanced when pyrazolo[3,4-d]pyrimidine-containing oligonucleotides are used as hybridization probes, making them useful as probes and primers for hybridization, amplification and sequencing procedures, particularly those in which single- or multiple-nucleotide mismatch discrimination is required.

Claims

1. A method for distinguishing polynucleotides with related sequences, the method comprising the following steps:

(a) providing an oligonucleotide having a defined sequence, wherein one or more purine residues of the oligonucleotide are substituted by a pyrazolo[3,4-d]pyrimidine;

(b) providing at least two polynucleotides, each of which comprises a target sequence, wherein one of the polynucleotides has a target sequence that is perfectly complementary to the oligonucleotide and at least one other of the polynucleotides has a related target sequence;

(c) separately incubating each of the polynucleotides with the oligonucleotide under hybridization conditions; and

(d) determining the degree of hybridization between the oligonucleotide and each of the polynucleotides,

wherein the polynucleotides are distinguished by different degrees of hybridization with the oligonucleotide.

2. The method according to claim 1, wherein the oligonucleotide further comprises a detectable label.

3. The method according to claim 2 wherein the detectable label is a fluorescent label.

4. The method according to claim 3 wherein the label is a fluorescein.

5. The method according to claim 3 wherein the oligonucleotide comprises multiple fluorescent labels.

6. The method according to claim 5 wherein the emission wavelengths of one of the fluorescent labels overlaps the absorption wavelengths of another of the fluorescent labels.

7. The method according to claim 3 wherein the oligonucleotide further comprises a quenching agent which quenches the fluorescence emission of the fluorescent label.

8. The method according to claim 7 wherein the fluorescent label is a fluorescein.

9. The method according to claim 8 wherein the quenching agent is tetramethylrhodamine.

10. The method according to claim 7, further comprising the step of altering the spatial relationship between the fluorescent label and the quenching agent subsequent to hybridization.

11. The method according to claim 10, wherein alteration of the spatial relationship between the fluorescent label and the quenching agent is accomplished by release of the label from the oligonucleotide.

12. The method according to claim 11, wherein release of label occurs as a result of exonuclease hydrolysis.

13. The method according to claim 12, wherein the degree of hybridization between the oligonucleotide and each of the polynucleotides is determined by the quantity of label that is released from the oligonucleotide subsequent to hybridization.

14. The method according to claim 1, wherein the polynucleotides differ by a single nucleotide.

15. The method according to claim 12, wherein the polynucleotides differ by a single nucleotide.

16. The method according to claim 1, wherein one or more guanine residues are substituted by 6-amino-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one.

17. The method according to claim 1, wherein one or more adenine residues are substituted by 4-amino-1H-pyrazolo[3,4-d]pyrimidine.

18. The method according to claim 1, wherein one or more purine residues are substituted by 1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one.

19. The method according to claim 1, wherein one or more purine residues are substituted by hypoxanthine.

20. The method according to claim 1, wherein the oligonucleotide further comprises one or more minor groove binder (MGB) moieties.

21. The method according to claim 20, wherein the minor groove binder moiety is selected from the group consisting of the trimer of 3-carbamoyl-1,2-dihydro-(3H)-pyrrolo[3,2-e]indole-7-carboxylate (CDPI₃) and the pentamer of N-methylpyrrole-4-carbox-2-amide (MPC₅).

22. The method according to claim 1, wherein the oligonucleotide is less than 21 nucleotides in length.

23. The method according to claim 1, wherein the degree of hybridization between the oligonucleotide and each of the polynucleotides is determined by the priming ability of the oligonucleotide.

24. The method according to claim 23, wherein priming occurs as part of an amplification reaction.

25. The method according to claim 24, wherein the amplification reaction is a polymerase chain reaction.

26. The method according to claim 3, wherein more than one oligonucleotide is used.

27. The method according to claim 26, wherein two oligonucleotides are used.

28. The method according to claim 27, wherein the first of the two oligonucleotides comprises a fluorescence donor and the second of the two oligonucleotides comprises a fluorescence acceptor, and further wherein the emission wavelengths of the fluorescence donor overlap the absorption wavelengths of the fluorescence acceptor.

29. A method for primer extension, the method comprising the following steps:

(a) providing a polynucleotide containing a target sequence,

(b) providing one or more oligonucleotide primers complementary to the target sequence,

(c) providing a polymerizing enzyme and nucleotide substrates, and

(d) incubating the polynucleotide, the oligonucleotide primers, the enzyme and the substrates under conditions favorable for polymerization;

wherein one or more purine residues of the one or more oligonucleotide primers are substituted by a pyrazolo[3,4-d]pyrimidine.

30. The method according to claim 29, wherein the method is part of an amplification reaction.

31. The method according to claim 30, wherein the amplification reaction is a polymerase chain reaction.

32. The method according to claim 29 wherein the method is used in the synthesis of a cDNA molecule.

33. A method for determining the nucleotide sequence of a polynucleotide, the method comprising the following steps:

(a) providing an array of oligonucleotides having different known sequences, wherein one or more purine residues in each of the oligonucleotides are substituted by a pyrazolo[3,4-d]pyrimidine;

(b) incubating the polynucleotide with the array under hybridization conditions, and

(c) determining to which of the oligonucleotides in the array the polynucleotide hybridizes;

wherein the nucleotide sequence of the polynucleotide is determined by examination of the sequences of the oligonucleotides to which the polynucleotide hybridizes.

34. A method for examining gene expression in a cell, the method comprising the following steps:

(a) providing a population of polynucleotides representative of the genes expressed in the cell,

(b) providing an array of oligonucleotides of different sequences, said array comprising a plurality of sites, wherein each site contains a unique oligonucleotide sequence, and wherein one or more purine residues in each of the oligonucleotides are substituted by a pyrazolo[3,4-d]pyrimidine;

(c) incubating the population of polynucleotides with the array under hybridization conditions, and

(d) determining which of the oligonucleotides in the array become hybridized to polynucleotides;

wherein detection of the sites on the array at which hybridization occurs is indicative of the pattern of gene expression in the cell.

35. A method for detecting a target sequence in a polynucleotide, wherein the polynucleotide is present in a mixture of other polynucleotides, and wherein one or more of the other polynucleotides in the mixture comprise sequences that are related but not identical to the target sequence, the method comprising:

(a) contacting the mixture of polynucleotides with an oligonucleotide, wherein

(i) the oligonucleotide has a sequence that is exactly complementary to said target sequence

(ii) one or more purine residues of the oligonucleotide are substituted by a pyrazolo[3,4-d]pyrimidine,

(iii) the oligonucleotide forms a stable hybrid with a sequence within said target sequence that is exactly complementary to the oligonucleotide, and

(iv) the oligonucleotide does not form a stable hybrid with any of the related sequences; and

(b) measuring hybrid formation, whereby hybrid formation is indicative of the presence of said target sequence.

36. The method according to claim 35, wherein an oligonucleotide that does not have one or more purine residues of the oligonucleotide substituted by a pyrazolo[3,4-d]pyrimidine forms stable hybrids with the target sequence and with the related sequences.

37. The method according to claim 36, wherein the target sequence and the related sequence differ by a single nucleotide.

38. The method according to claim 37, wherein the target sequence comprises an allele of a polymorphic sequence.

39. The method according to claim 38, wherein one or more of the related sequences comprise different alleles of said polymorphic sequence.

40. The method according to claim 37, wherein said oligonucleotide further comprises an minor groove binding moiety.

41. The method according to claim 40, wherein the minor groove binding moiety is selected from the group consisting of the trimer of 3-carbamoyl-1,2-dihydro-(3H)-pyrrolo[3,2-e]indole-7-carboxylate (CDPI₃) and the pentamer of N-methylpyrrole-4-carbox-2-amide (MPC₅).

42. The method according to claim 35 wherein the oligonucleotide comprises a 5'"'"' end and a 3'"'"' end, wherein the 3'"'"' end comprises a 3'"'"'-hydroxyl group.

43. The method according to claim 42, wherein hybridized nucleic acids are identified by extending the 3'"'"' end of the oligonucleotide with a polymerizing enzyme.

44. The method according to claim 43 wherein the polymerizing enzyme is a thermostable enzyme.

45. The method according to claim 43, wherein the oligonucleotide is extended in an amplification reaction.

46. The method according to claim 45, wherein the amplification reaction is a polymerase chain reaction.